Project description:Scabies is a human skin disease due to the burrowing ectoparasite Sarcoptes scabiei resulting in intense itching and inflammation and manifesting as skin allergy. Little is known about the specific scabies molecules and genes involved in the host inflammatory and immunologic responses. We interrogated the transcriptome profiles of skin biopsies using next generation sequencing and a combined clustering and pathway mapping approach which will enable us in the identification of key signaling events in the host immune and inflammatory responses to S. scabiei infestation. With the comprehensive analysis of RNA-seq results, it has been found that the immune response of host inhibits S. scabiei immune pathway, proliferation and metabolism signaling pathways, out of which the signaling pathway seems to be the main pathway in innate immune response of S. scabiei. The analysis of immune pathway, hydrolase and allergen will contribute to the research of S. scabiei pathogenesis, diagnosis and development of vaccines.
Project description:Background: The parasitic mite Sarcoptes scabiei is an economically highly significant parasite of the skin of humans and animals worldwide. This mite causes a neglected tropical disease (NTD), called scabies - one of the commonest dermatological problems globally, resulting in major morbidity, disability, stigma and poverty. In hyperendemic situations, scabies is often associated with secondary opportunistic bacterial infections/diseases - a major concern in children. Although some stages of this mite can be treated with drugs, resistance against some drugs is emerging, and there is no vaccine available against scabies. Here, we report molecular resources (including a high-quality genome as well as transcriptomic and proteomic data sets) for S. scabiei to aid basic and applied research of this and related mites.
Project description:Presently, there is a dearth of proteomic data for parasitic mites and their relationship with the host animals. Here, using a high throughput LC-MS/MS-based approach, we undertook the first comprehensive, large-scale proteomic investigation of egg and adult female stages of the scabies mite, Sarcoptes scabiei – one of the most important parasitic mites of humans and other animals worldwide. In total, 1,761 S. scabiei proteins were identified and quantified with high confidence. Bioinformatic analyses revealed differentially expressed proteins to be involved predominantly in biological pathways or processes including genetic information processing, energy (oxidative phosphorylation), nucleotide, amino acid, carbohydrate and/or lipid metabolism, and some adaptive processes. These proteomic data set will enable future molecular, biochemical and physiological investigations of early developmental stages of S. scabiei and the discovery of novel interventions targeting the egg stage, given its non-susceptibility to current acaricidal treatments.
Project description:The purpose of this study was to identify genes in keratinocytes and fibroblasts in human skin equivalents that changed expression in response to the burrowing of live scabies mites. Four biological replicates for the uninfested control condition and five biological replicates for the treatment conditions (live mites, mite extract) were processed for gene expression analysis using Affymetrix Human Gene 1.0 ST arrays.
Project description:The purpose of this study was to identify genes in keratinocytes and fibroblasts in human skin equivalents that changed expression in response to the burrowing of live scabies mites.
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.
Project description:Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation. In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.